ABX464-101
44 evidence topics · 12 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Proof-of-concept purpose described by the sponsor
Location and study date
Results posting date
Registered locations
Centers and countries reported by the sponsor
Centers and countries at the time of the extension study authorization
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Interventional model description | “Double-blind, placebo-controlled, randomized study” |
| Masking description | “Double-Blind Treatment” |
| Primary purpose | “Treatment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “32” |
Randomized, double-blind design and central endoscopy reading described by the sponsor
Induction phase of the phase 2 program
Eligibility criteria
Disease activity and background therapy in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms in the ClinicalTrials.gov record
Permitted background therapy at stable doses
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Clinical remission registered as the primary efficacy endpoint among secondary outcomes
Other registered secondary outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size stated in the ABX464-102 protocol
Description of analysis sets
Analysis populations in the posted results
Statistical tests in the posted results
| Outcome | Method |
|---|---|
| Treatment-emergent adverse events | “Chi-squared” |
| Clinical remission | “Chi-squared” |
| Fecal calprotectin | “ANCOVA” |
| Total Mayo score | “ANCOVA” |
| Partial Mayo score | “ANCOVA” |
Results
Participant disposition
Participants completing per protocol, as reported by the sponsor
Roll-over into the ABX464-102 extension
Baseline characteristics
Baseline disease activity, disease duration, and prior advanced therapy
No evidence found.
Efficacy results
Clinical remission, clinical response, and endoscopic outcomes at week 8 reported by the sponsor
Week 8 results stated in the ABX464-102 protocol
Statistical comparisons of week 8 outcomes reported by the sponsor
Topline statistical comparisons and fecal calprotectin reported in 2018
Clinical remission at week 8 in the posted results, with arm titles as the record lists them
| Field | First arm listed | Second arm listed |
|---|---|---|
| Arm/group title | “ABX464 Matching Placebo Treatment Arm” | “ABX464 Treatment Arm” |
| Overall number of participants analyzed | “20” | “9” |
| Participants in clinical remission | “7” | “1” |
Mayo score change and fecal calprotectin at week 8 in the posted results
| Outcome | ABX464 (n=20) | Placebo (n=9) |
|---|---|---|
| Change from baseline in total Mayo score, mean (SD) | “-4.6(2.8)” | “-2.1(2.5)” |
| Change from baseline in partial Mayo score, mean (SD) | “-3.9(2.2)” | “-1.8(2.0)” |
| Participants with fecal calprotectin above 50 µg/g | “15” | “8” |
miR-124 expression in blood during ABX464-101 and ABX464-102
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Deaths, serious adverse events, and other adverse events in the posted results
| Measure, affected / at risk (%) | ABX464 | Placebo |
|---|---|---|
| All-cause mortality | “0/23 (0.00%)” | “0/9 (0.00%)” |
| Serious adverse events, total | “0/23 (0.00%)” | “1/9 (11.11%)” |
| Nephrolithiasis left side (serious) | “0/23 (0.00%)” | “1/9 (11.11%)” |
| Other (not including serious) adverse events, total | “18/23 (78.26%)” | “5/9 (55.56%)” |
Other adverse events in at least two participants of either group
| Event, affected / at risk (%) | ABX464 | Placebo |
|---|---|---|
| Abdominal pain | “4/23 (17.39%)” | “1/9 (11.11%)” |
| Headache | “4/23 (17.39%)” | “0/9 (0.00%)” |
| Abdominal pain upper | “3/23 (13.04%)” | “0/9 (0.00%)” |
| Nausea | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Chest pain | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Influenza like illness | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Hypophosphataemia | “1/23 (4.35%)” | “2/9 (22.22%)” |
Adverse event collection period
Study limitations
Summary
ABX464-101 was a randomized, double-blind, placebo-controlled phase 2a study in which 32 participants with moderately to severely active ulcerative colitis were randomized 2:1 to obefazimod 50 mg (23 participants) or placebo (9 participants) once daily for 8 weeks, at sites in six European countries. The registered primary endpoint was the number of participants with treatment-emergent adverse events; clinical remission by the total Mayo score at week 8 was registered as an outcome described as the “primary efficacy endpoint”. Efficacy was analyzed in participants without major protocol deviations who completed day 56 (20 receiving obefazimod and 9 receiving placebo), and the sponsor reported that 29 of the 32 participants “completed the study per protocol”. The planned sample size, stated in the ABX464-102 protocol, was a maximum of 30 participants, and no power calculation was located. Clinical remission at week 8 was reported as 35.0% with obefazimod and 11.1% with placebo, a difference the sponsor reported as not significant. The posted record lists the arm titles of the clinical remission outcome in the reverse order of the other outcomes, so its arm labels do not match its participant counts. The posted results analyze the change in partial and total Mayo scores by ANCOVA, whereas a 2019 press release reports p=0.029 for both, naming a likelihood ratio chi-square test for the partial Mayo score, and the 2018 topline release reports p<0.03 for the total Mayo score. Placebo clinical response is given as 33.0% in the ABX464-102 protocol and 33.3% in a 2021 press release. The sponsor describes the study drug as a tablet, and the posted record as a capsule. All 32 participants were White. Baseline disease activity, disease duration, and prior advanced therapy exposure were not reported in the readable sources, because the protocol and statistical analysis plan posted on ClinicalTrials.gov are image-only scans. No health-related quality of life results were located.